Lipid Goal Attainment and Prescription Behavior in Asian Patients with Acute Coronary Syndromes: Experience from a Tertiary Hospital
Open accessAbstract
Lipid goal attainment studies in Asian patients with acute coronary syndrome (ACS) are limited. The objectives of this study were to determine low-density lipoprotein cholesterol (LDL-C) goal attainment rate at 4 months, and to examine prescription behavior influencing lipid goal attainment in Asian patients with ACS. A retrospective analysis of 267 patients with ACS was performed. The mean follow-up duration was 41.2 ± 10.7 months. LDL-C goal attainment rate was highest at 4 months (36.7%) but declined progressively throughout follow-up. More than 85% of patients were discharged with equipotent statin dose of 2 (equivalent to simvastatin 20 mg) or less. In patients who did not attain LDL-C goals, the statin dose remained low throughout follow-up because of a lack in responsive dose titration. Aggressive lipid-lowering therapy should be initiated early to improve goal attainment in these high-risk patients.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
This challenge is particularly evident in patients with high atherosclerotic risk and those post-acute coronary syndrome, even in the primary care setting.
“This challenge is particularly evident in patients with high atherosclerotic risk and those post-acute coronary syndrome, even in the primary care setting.78,80,81”
From Interventions to improve adherence to lipid-lowering drugs: a systematic review and meta-analysis (2025) · cites this paper as [80]
The Discussion reports lower LDL-C goal attainment among higher-risk patients and says attainment is even lower in patients with acute coronary syndrome; the study found 36.7% reached its LDL-C target at four months. The Methods describe patients admitted to a tertiary hospital, not a primary care population, so this source does not support the primary-care part of the sentence. (LLM, conf=0.87)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group (2010) · The Lancet · doi:10.1016/s0140-6736(10)60310-8 · Cited by 558 · see citing works
Flagged first, then by citations
Research works printed but not linked: 21
- [1]De Lemos JA Blazing MA Wiviott SD Early intensive vs. delayed conservative simvastatin strategy in patients with acute coronary syndrome: phase Z of the A to Z trial JAMA 2004 292 1307 16 15337732
- [2]Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipide lowering with statins after acute coronary syndromes N Engl J Med 2004 350 1495 504 15007110
- [3]Pedersen TR Faergeman O Kastelein JJ High dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study, a randomized controlled trial JAMA 2005 294 2437 45 16287954
- [5]Grundy SM Cleeman JI Merz CN Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Circulation 2004 110 227 39 15249516
- [6]Kim HS Wu YF Lin SJ Current status of cholesterol goal attainment after statin therapy among patients with hyper-cholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-ASIA) study Curr Med Res Opin 2008 24 1951 63 18547466
- [7]Assman G Benecke H Neiss A Cullen P Schulte H Bestehorn K Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians’ Experience and Evaluation) Eur J Cardiovasc Prev Rehabil 2006 13 776 83 17001218
- [8]Ho KT Chin KW Ng KS The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease Am J Cardiovasc Drugs 2006 6 383 91 17192128
- [9]Van Ganse E Laforest L Alemao E Davies G Gutkin S Yin D Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study Curr Med Res Opin 2005 21 1389 99 16197657
- [10]Park JE Chiang CE Munawar M Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survery Eur J Prev Cardiol 2012 19 781 94 21450606
- [11]Andrikopoulous G Tzeis S Nikas N Short-term outcome and attainment of secondary prevention goals in patients with acute coronary syndrome-Results from the countrywide TARGET study Int J Cardiol 2012 published online instead of print 10.1016/j.ijcard.2012.10.049 23186596 · DOI
- [12]Lindgren P Borgstrom F Stalhammar J Alemao E Yin DD Jönsson L Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice Eur J Cardiovasc Prev Rehabil 2005 12 530 4 16319541
- [13]Lee K Lee V Chan WK Cholesterol goal attainment in patients with coronary heart disease and elevated coronary risk: Results of the Hong Kong hospital audit study Value Health 2008 11 S91 8 18387073
- [14]Maron D Fazio S Linton MF Current perspectives on statins Circulation 2000 101 207 13 10637210
- [15]Jones PH McKenney JM Karalis DG Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia Am Heart J 2005 149 E1 8 15660024
- [16]Baigent C Blackwell L Emberson J Efficacy and safety of intensive LDL-cholesterol-lowering therapy: A meta-analysis of data from 170,000 participants in 26 randomized trials Lancet 2010 376 1670 81 21067804 PMC2988224
- [17]McKeeny JM Davidson MH Saponaro J Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin J Cardiovasc Pharmacol 2005 46 594 9 16220065
- [18]Martineau P Gaw A de Teresa E Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: The Achieve Cholesterol Targets Fast with Atorvastatin Startified Titration (ACTFAST-1) study Atherosclerosis 2007 191 135 46 16643923
- [19]Farsang C Athyros V Gaw A A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study Curr Med Res Opin 2007 23 1945 56 17626713
- [20]Ducobu J Claeys M Commers K Efficacy of atorvastatin after LDL-cholesterol- based dose selection in high risk dyslipidaemic patients: results of the target dose study Curr Med Res Opin 2007 23 1821 7 17609019
- [21][No authors listed] Flexible initial dosing of atorvastatin based upon initial low-density lipoprotein cholesterol levels in type 2 diabetics patients Korean J Intern Med 2008 23 22 9 18363276 PMC2686951
- [22]Ferrer-Garcia JC Snachez-Ballester E Albalat-Galera R Berzosa- Sanchez M Herrera-Ballester A Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes J Cardiovasc Pharmacol Ther 2008 13 183 8 18635754
Cited by
Sorted by citations
Interventions to improve adherence to lipid-lowering drugs: a systematic review and meta-analysis
Yow, D. K. W., Ang, W. J., Yap, H. J., Ito, S., Liu, J., Ko, J., Tan, D. S.-Y., Lorenzatti, A., & Ang, C.-S. (2025) · eClinicalMedicine · doi:10.1016/j.eclinm.2025.103270 · Cited by 5 · see citing works
“78,80,81 As evidenced by an urgent call made by the American College of Cardiology for more aggressive advocacy for the attainment of LDL-C control, physician inertia is a known phenomenon contributing to the poor rates of target LDL-C attainment.”
- Authors
- Chin, C. W., Gao, F., Le, T., & Tan, R.
- Affiliations
- National Heart Centre Singapore (SG)
- Department of Cardiology, National Heart Center Singapore, Singapore.
- Corresponding author
- Chin, Calvin W
- ORCID
- Venue
- Clinical Medicine Insights: Cardiology
- Publisher
- SAGE Publications
- Published
- 2013-01
- Volume
- 7
- Pages
- CMC.S11488
- ISSN
- 1179-5468 (ISSN-L)
- PMC
- PMC3603384
- OpenAlex
- W2136922390
- Cited by
- 17
- References
- 1
- Citations by year
- 2025: 2 · 2022: 1 · 2019: 4 · 2018: 2 · 2017: 1 · 2016: 2 · 2015: 2 · 2014: 3
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Clinical Medicine Insights Cardiology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Surgery › Coronary Interventions and Diagnostics
- Keywords
- acute coronary syndrome, lipid goal attainment, LDL cholesterol, statin dose titration, statin prescribing, lipid-lowering therapy, Asian patients, secondary prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
